Kimia Farma Continues To Be Committed to Supporting the Independence Of The Pharmaceutical Industry In The Country

Kimia Farma President Director, David Utama. (Photo: Doc. Kimia Farma)

JAKARTA - PT Kimia Farma Tbk (KAEF) is committed to continuing to support the independent program of the pharmaceutical industry in the country. One of the things the company does through its subsidiary, namely PT Kimia Farma Sungwun Pharmacopia, is to develop and produce domestic medicinal raw materials (BBO).

The construction of the BBO production facility located in Cikarang, West Java, which was completed in 2018, continues to innovate to realize national health security through BBO production.

Kimia Farma President Director David Utama targets the production of 28 BBOs to be achieved by 2024. Thus, BBO imports can be reduced by up to 20 percent.

"We will develop and produce a total of 28 BBO which will be produced until 2024. It is expected to reduce imports by 17-20 percent," David said at a press conference at PT Kimia Farma Sungwun Pharmacopia, Cikarang, Monday, October 3.

Furthermore, David said, if the reduction in BBO imports can be realized, the government can save up to IDR 3.7 trillion. As for every year, KFSP's BBO production has been able to suppress imports since 2020.

For information, to this day PT Kimia Farma Sungwun Pharmacopia already has a certificate of Good Manufacturing Practice of Active Drug Raw Materials from the Indonesian Food and Drug Supervisory Agency (BPOM).

The development of Drug Raw Materials is carried out by government programs and national needs priorities, where until 2022 has succeeded in producing 12 BBO items that have a GMP certificate from the Indonesian POM so that they are ready to be used by the entire domestic Pharmaceutical Industry.

With the improvement in the quality of production facilities, as well as innovations from Kimia Farma as a member of the Pharmaceutical BUMN Holding, it is hoped that Kimia Farma can play a role in reducing the number of imports of medicinal raw materials or Active Pharmaceutical Ingredients (API) in Indonesia, and can continue to optimize the use of domestic BBO.